Expression and Regulation of Osteoprotegerin in Adipose Tissue
1
조회
0
다운로드
0
인용
0
참고문헌
초록
Abstract
Purpose: Osteoprotegerin (OPG), a potent inhibitor of osteoclastic bone resorption, has a variety of biological functions that include anti-inflammatory effects. Adipocytes and osteoblasts share a common origin, and the formation of new blood vessels often precedes adipogenesis in developing adipose tissue microvasculature. We examined whether OPG is secreted from adipocytes, therefore contributing to the prevention of neovascularization and protecting the vessels from intimal inflammation and medial calcification. Materials and Methods: The mRNA expression of OPG and receptor activator of NF-κB ligand (RANKL) was measured in differentiated 3T3L1 adipocytes and adipose tissues. Results: OPG mRNA expression increased with the differentiation of 3T3L1 adipocytes, while RANKL expression was not significantly altered. OPG mRNA was expressed at higher levels in white adipose tissue than in brown adipose tissue and was most abundant in the epididymal portion. In differentiated 3T3L1 adipocytes, Rosiglitazone and insulin reduced the OPG/RANKL expression ratio in a dose- and time- dependent manner. In contrast, tumor necrosis factor-α (TNF-α) increased the expression of both OPG and RANKL in a time-dependent manner. The OPG/RANKL ratio was at a maximum two hours after TNF-α treatment and then returned to control levels. Furthermore, OPG was abundantly secreted into the media after transfection of OPG cDNA with Phi C31 integrase into 3T3L1 cells. Conclusion: Our results indicate that OPG mRNA is expressed and regulated in the adipose tissue. Considering the role of OPG in obesity-associated inflammatory changes in adipose tissue and vessels, we speculate that OPG may have both a protective function against inflammation and anti-angiogenic effects on adipose tissue.
참고문헌 (26)
- Lacey DL, "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation", 93, pp.165~176 (1998)
- Simonet WS, "a novel secreted protein involved in the regulation of bone density", 89, pp.309~319 (1997)
- Bucay N, "Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification", 12, pp.1260~1268 (1998)
- Emery JG, "Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL", 273, pp.14363~14367 (1998)
- Malyankar UM, "Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells", 275, pp.20959~20962 (2000)
- Collin-Osdoby P, "Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis", 276, pp.20659~20672 (2001)
- Sattler AM, "Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease", 74, pp.103~106 (2003)
- Min JK, "Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand", 278, pp.39548~39557 (2003)
- Price PA, "Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D", 21, pp.1610~1616 (2001)
- Browner WS, "Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women", 86, pp.631~637 (2001)
- Schoppet M, "Increased osteoprotegerin serum levels in men with coronary artery disease", 88, pp.1024~1028 (2003)
- Jono S, "Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease", 106(s), pp.1192~1194 (2002)
- Schoppet M, "Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men", 107, pp.e76~ (2003)
- Rasmussen LM, "Osteoprotegerin and diabetic macroangiopathy", 37, pp.90~94 (2005)
- Imhof BA, "Angiogenesis and inflammation face off", 12, pp.171~172 (2006)
- Nakashima T, "Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappa B ligand: modulation of the expression by osteotropic factors and cytokines", 275, pp.768~775 (2000)
- Collin-Osdoby P, "Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis", 276, pp.20659~20672 (2001)
- Rupnick MA, "Adipose tissue mass can be regulated through the vasculature", 99, pp.10730~10735 (2002)
- Hausman GJ, "Adipose tissue angiogenesis", 82, pp.925~934 (2004)
- Groth AC, "A phage integrase directs efficient site-specific integration in human cells", 97, pp.5995~6000 (2000)
- Hofbauer LC, "Clinical implications of the osteoprotegerin", RANKL, pp.2004, 292[DOI]
- Trayhurn P, "Adipokines: inflammation and the pleiotropic role of white adipose tissue", 92, pp.347~355 (2004)
- Collin-Osdoby P, "Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin", 95, pp.1046~1057 (2004)
- Pantouli E, "Inflammatory cytokines activate p38 MAPK to induce osteoprotegerin synthesis by MG-63 cells", 329, pp.224~229 (2005)
- Xu H, "Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance", 112, pp.1821~1830 (2003)
- Olesen P, "Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha", 48, pp.561~568 (2005)